Koers Cytosorbents Corp OTC Bulletin Board
Aandelen
CTSO
US23283X1072
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 41,33 mln. 38,21 mln. | Omzet 2025 * | 47,76 mln. 44,15 mln. | Marktkapitalisatie | 45,16 mln. 41,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -18,49 mln. | Nettowinst (verlies) 2025 * | -9 mln. -8,32 mln. | EV/omzet 2024 * | 1,09 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,95 x |
K/w-verhouding 2024 * |
-2,31
x | K/w-verhouding 2025 * |
-4,09
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,8% |
Recentste transcriptie over Cytosorbents Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Phillip Chan
CEO | Chief Executive Officer | 53 | 24-07-08 |
Vincent Capponi
PSD | President | 66 | 25-04-02 |
Kathleen Bloch
DFI | Director of Finance/CFO | 69 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Bator
CHM | Chairman | 60 | 14-07-15 |
Phillip Chan
CEO | Chief Executive Officer | 53 | 24-07-08 |
Edward Jones
BRD | Director/Board Member | 75 | 01-04-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,06% | 225 mld. | |
+12,07% | 186 mld. | |
+13,88% | 135 mld. | |
+27,12% | 107 mld. | |
+0,91% | 63,56 mld. | |
+6,74% | 51,32 mld. | |
+13,39% | 51,04 mld. | |
+8,81% | 43,3 mld. | |
+4,14% | 36,99 mld. |